Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 7/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5689888 | 0.87 | KDM4E (0.51) | IDO1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2397559 | 0.83 | KDM4E (0.48) | IDO1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL4092924 | 0.79 | IDO1 (0.58) | IDO1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL8685889 | 0.77 | IDO1 (0.55) | IDO1KDM4EALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3150864 | 0.75 | IDO1 (0.54) | IDO1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL27749752 | 0.75 | KDM4E (0.57) | IDO1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2687045 | 0.74 | KDM4E (0.64) | IDO1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL3904321 | 0.73 | IDO1 (0.62) | IDO1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL29003631 | 0.72 | KDM4E (0.62) | IDO1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL820361 | 0.72 | IDO1 (0.61) | IDO1KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110209699-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS, LLC | 2011-09-01 | — | — | US | disclosed |
| US-20050090455-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS, LLC. | 2005-04-28 | — | — | US | disclosed |
| US-20050043282-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS LLC | 2005-02-24 | — | — | US | disclosed |
| US-20050020665-A1 | Pharmaceutical composition for treating multiple sclerosis | NEU INGO (DE) | 2005-01-27 | — | — | US | disclosed |
| EP-0279263-B1 | INDOLE, BENZOFURAN, BENZOTHIOPHENE CONTAINING LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1993-08-04 | — | — | EP | disclosed |
| US-4873259-A | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1989-10-10 | — | — | US | disclosed |
| EP-0279263-A2 | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090455-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | HSD11B2, CYP17A1, ALOX5 | ALOX5 3/4885IDO1 1499/4885KDM4E 1785/4885 |
| US-20050020665-A1 | Pharmaceutical composition for treating multiple sclerosis | NR1H3, NR1H2, NR1H4 | ALOX5 1826/4885IDO1 2743/4885KDM4E 3284/4885 |
| US-20050043282-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | HSD11B2, CYP17A1, ALOX5 | ALOX5 3/4885IDO1 1437/4885KDM4E 1676/4885 |
| US-20110209699-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | HSD11B2, CYP17A1, ALOX5 | ALOX5 3/4885IDO1 1499/4885KDM4E 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.